L-alanyl-L-glutamine dipeptide–supplemented total parenteral nutrition reduces infectious complications and glucose intolerance in critically ill patients: The French controlled, randomized, double-blind, multicenter study*-Reference-Cited by-同舟云学术

L-alanyl-L-glutamine dipeptide–supplemented total parenteral nutrition reduces infectious complications and glucose intolerance in critically ill patients: The French controlled, randomized, double-blind, multicenter study*

Published:2006-03 Issue:3 Volume:34 Page:598-604
ISSN:0090-3493
Container-title:Critical Care Medicine
language:en
Short-container-title:Critical Care Medicine

Author:

Déchelotte Pierre,Hasselmann Michel,Cynober Luc,Allaouchiche Bernard,Coëffier Moïse,Hecketsweiler Bernadette,Merle Véronique,Mazerolles Michel,Samba Désiré,Guillou Yves Marie,Petit Jean,Mansoor Odile,Colas Gabriel,Cohendy Robert,Barnoud Didier,Czernichow Pierre,Bleichner Gérard

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Critical Care and Intensive Care Medicine

Reference44 articles.

1. Glutamine: The Emperor or His Clothes?

2. Nutritional Support

3. Plasma Glutamine Levels in Septic Patients

4. Randomised trial of glutamine-enriched enteral nutrition on infectious morbidity in patients with multiple trauma

Cited by 275 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the role of antioxidants in sepsis-associated oxidative stress: a comprehensive review;Frontiers in Cellular and Infection Microbiology;2024-03-06

2. Glutamine Supplementation as an Anticancer Strategy: A Potential Therapeutic Alternative to the Convention;Cancers;2024-03-05

3. Immunonutrients and intestinal microbiota: a gap in the literature;Critical Reviews in Food Science and Nutrition;2023-09-26

4. Clinical Effects of Postoperative Parenteral Glutamine-Dipeptide Supplementation in Surgical Intensive Care Unit 3 Patients: a Systematic Review and Meta-analysis;2023-08-16

5. L-Ala-L-Gln Suppresses Hypoxic Phenotype and Fibrogenic Activity of Rat Perineurial Fibroblasts;CNS & Neurological Disorders - Drug Targets;2023-06